MTHFSD

Across TCGA pan-cancer cohorts, MTHFSD Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MTHFSD data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher MTHFSD Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MTHFSD expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

SKCM, LUAD, and STAD are the cancer types where MTHFSD Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.230	0.781	.004	18	view →
LUAD	OS	Median	All	0.233	0.673	.006	12	view →
STAD	OS	Median	IV	0.805	0.283	.031	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MTHFSD–SKCM (OS)

Open the SKCM breakdown →